Melanoma Clinical Trials in Salt Lake City

Showing 41-60 of 270 trials

Analyzing Clinical Outcomes and Genomic Data of American Indian Patient Population

NCT05863052

The aim of this study is to describe the outcomes in American Indian patients receiving immunotherapy in a multi-institution retrospective study at several other high-volume centers that care for this patient population and to identify any healthcare disparities that can lead to future interventional studies.

Immune Checkpoint InhibitorsMetastatic Solid TumorNonsmall Cell Lung Cancer+4 more

University of Oklahoma72 participantsStarted Jan 2022

Tucson, Arizona, United States • Albuquerque, New Mexico, United States • Oklahoma City, Oklahoma, United States +3 more locations

COMPLETEDPhase 2< 1 mile

A Study to Evaluate the Efficacy and Safety of Autogene Cevumeran (RO7198457) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Participants With Previously Untreated Advanced Melanoma.

NCT03815058

This study will evaluate the efficacy, safety, pharmacokinetics, and patient-reported outcomes (PROs) of autogene cevumeran (RO7198457) plus pembrolizumab compared with pembrolizumab alone in patients with previously untreated advanced melanoma.

Advanced Melanoma

Genentech, Inc.131 participantsStarted Dec 2018

Duarte, California, United States • La Jolla, California, United States • San Francisco, California, United States +38 more locations

Analyzing Clinical Outcomes and Genomic Data of American Indian Patient Population

A Study to Evaluate the Efficacy and Safety of Autogene Cevumeran (RO7198457) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Participants With Previously Untreated Advanced Melanoma.

Melanoma Trials in Other Cities

Neoadjuvant Ipilimumab/Nivolumab for Patients With Recurrent, High Risk, Resectable Melanoma

Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment Trial

Postmarketing Prospective Study of Melanoma Patients Treated With IMLYGIC® to Characterize Risk of Herpetic Infection

A Study of Modakafusp Alfa (TAK-573) Given by Itself and Together With Pembrolizumab in Adults With Advanced or Metastatic Solid Tumors

A Study of MGC026 in Participants With Advanced Solid Tumors

Avelumab With or Without Cetuximab in Treating Patients With Advanced Skin Squamous Cell Cancer

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

Ipilimumab With or Without Bevacizumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery

Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions

A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7502175 as a Single Agent and in Combination With Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid Tumors

A Trial to Learn if Fianlimab and Cemiplimab Are Safe and Work Better Than Anti-PD1 Alone in Adult Participants With Resectable Stage 3 or 4 Melanoma

A Study to Learn About the Long-Term Health of Adult Participants From a Previous Study of a New Melanoma Treatment

A Study to Assess Adjuvant Immunotherapy With Nivolumab Plus Relatlimab Versus Nivolumab Alone After Complete Resection of Stage III-IV Melanoma

Study of Lifileucel (LN-144), Autologous Tumor Infiltrating Lymphocytes, in the Treatment of Patients With Metastatic Melanoma

Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)

Patient Satisfaction With Appearance, Scar Outcome and Quality of Life After Skin Cancer Surgery

Observational Basket Trial to Collect Tissue to Develop and Train a Live Tumor Diagnostic Platform

Genetic Analysis of Blood and Tissue Samples From Patients With Advanced Cancer, Moonshot Study

Other Conditions in Salt Lake City